BCAX vs CBIO: fair value comparison
Bicara Therapeutics Inc. and Crescent Biopharma, Inc. · Updated 2026-10-19
BCAX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BCAX currently ranks higher by quality score.
| BCAX | CBIO | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $16.78 | $11.84 |
| 12-month range | $13.93–$30.40 | $8.94–$26.98 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #224 of 301 Healthcare | #226 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: BCAX fair value analysis · CBIO fair value analysis